down arrow

Vaccinex, Inc.

  • Market Cap: N/A
  • Industry: Pharmaceuticals & Biotechnology
  • ISIN: US9186403013
USD
0.70
0.03 (4.22%)

Dec 04

NAS

 Click here to see other stocks
  • Price Points
  • Score
  • Mojo Parameters
  • Total Return
  • News and Corporate Actions
  • Key factors
  • Shareholding
  • Financials
  • CompanyCV
stock-summaryPrice Point
High/Low

1Day

0.700.70

52 Week

0.254.35
Valuation
Technical
Day's Volume

CASH

564

Shareholding (Dec 2024)

FII

0.04%

Held by 5 FIIs

DII

99.68%

Held by 0 DIIs

Promoter

0.00%

How big is Vaccinex, Inc.?

22-Jun-2025

As of Jun 18, Vaccinex, Inc. has a market capitalization of 1.90 million, with net sales of 0.59 million and a net profit of -18.63 million over the last four quarters. The company has shareholder's funds of -2.49 million and total assets of 2.60 million as of Dec 24.

Market Cap: <BR>As of Jun 18, Vaccinex, Inc. has a market capitalization of 1.90 million, categorizing it as a Micro Cap company.<BR><BR>Recent Quarterly Performance: <BR>For the latest four quarters, Vaccinex, Inc. reported net sales of 0.59 million and a net profit of -18.63 million.<BR><BR>Balance Sheet Snapshot: <BR>As of Dec 24, the company has shareholder's funds of -2.49 million and total assets amounting to 2.60 million.

Read More

What does Vaccinex, Inc. do?

22-Jun-2025

Vaccinex, Inc. is a clinical-stage biotechnology company focused on developing targeted biotherapeutics for serious diseases. As of December 2024, it reported net sales of $0 million and a net loss of $3 million, with a market cap of $1.90 million.

Overview:<BR>Vaccinex, Inc. is a clinical-stage biotechnology company engaged in the discovery and development of targeted biotherapeutics, focused on serious diseases within the Pharmaceuticals & Biotechnology industry.<BR><BR>Financial Snapshot:<BR>Most recent Net Sales: 0 Million (Quarterly Results - Dec 2024) <BR>Most recent Net Profit: -3 Million (Quarterly Results - Dec 2024) <BR>Market-cap: USD 1.90 Million (Micro Cap) <BR><BR>Key Metrics:<BR>P/E: NA (Loss Making) <BR>Industry P/E: NA <BR>Dividend Yield: 0.00% <BR>Debt Equity: 0.43 <BR>Return on Equity: 797.03% <BR>Price to Book: -0.77 <BR><BR>Contact Details:<BR>Address: 1895 Mount Hope Ave, ROCHESTER NY: 14620-4540 <BR>Tel: 1 585 2712700 <BR>Fax: 1 585 2712765 <BR>Website: http://www.vaccinex.com/

Read More

Is Vaccinex, Inc. overvalued or undervalued?

25-Jun-2025

As of November 8, 2021, Vaccinex, Inc. is considered overvalued with negative financial ratios and a significant stock return decline of -87.21%, indicating a deterioration in its financial standing compared to peers like Champions Oncology, Inc. and C4 Therapeutics, Inc.

As of 8 November 2021, the valuation grade for Vaccinex, Inc. moved from risky to does not qualify, indicating a significant deterioration in its financial standing. The company is currently considered overvalued, given its negative financial ratios, including a price-to-book value of -0.92 and an EV to EBITDA of -0.07, which suggest that the company is not generating positive returns or value for shareholders. <BR><BR>In comparison to its peers, Vaccinex's EV to EBIT ratio of -0.06 stands in stark contrast to Champions Oncology, Inc., which has a P/E ratio of 17.32, highlighting the disparity in financial health and market perception. Other peers, such as C4 Therapeutics, Inc., are also in a risky category with a P/E of -1.02, but they still reflect a better valuation outlook than Vaccinex. The company's significant underperformance is further illustrated by its one-year stock return of -87.21% compared to a 10.26% return for the S&P 500, reinforcing the notion that it is overvalued in its current state.

Read More

Is Vaccinex, Inc. technically bullish or bearish?

20-Sep-2025

As of September 8, 2025, Vaccinex, Inc. is in a bearish trend with weak strength, indicated by bearish moving averages and KST, underperforming the S&P 500 with a 1-year return of -86.43%.

As of 8 September 2025, the technical trend for Vaccinex, Inc. has changed from mildly bearish to bearish. The current technical stance is bearish with weak strength. Key indicators include bearish moving averages on the daily timeframe, a bearish KST on both weekly and monthly timeframes, and mildly bearish signals from Bollinger Bands. The MACD shows mildly bullish signals on the weekly and monthly, but this is overshadowed by the overall bearish trend. <BR><BR>In terms of performance, the stock has underperformed significantly compared to the S&P 500, with a 1-year return of -86.43% versus the S&P 500's 17.14%, and a staggering -99.94% over the past 5 and 10 years.

Read More
iScoreScore
Click here to find our call on this stock
Strong Sell
Sell
Hold
Buy
Strong Buy

MarketsMojo — Loved in India, Now Global

The power of Mojo is now in 29 countries. Explore global equities with the same cutting-edge features you love.

Dashboard
Icon
Unrated Stock - No Analysis Available
stock-summaryMojo Parameters
Mojo Parameters
Stock DNA
stock-summary
Industry

Pharmaceuticals & Biotechnology

stock-summary
Market cap

USD 1 Million ()

stock-summary
P/E

NA (Loss Making)

stock-summary
Industry P/E

NA

stock-summary
Dividend Yield

0.00%

stock-summary
Debt Equity

0.43

stock-summary
Return on Equity

797.03%

stock-summary
Price to Book

-0.59

Revenue and Profits:
Net Sales:
0 Million
(Quarterly Results - Dec 2024)
Net Profit:
-3 Million
stock-summaryTotal Returns
Total Returns (Price + Dividend) stock-summary
TimePeriod
Price Return
Dividend Return
Total Return
3 Months
28.25%
0%
28.25%
6 Months
-1.48%
0%
-1.48%
1 Year
-84.76%
0%
-84.76%
2 Years
-91.94%
0%
-91.94%
3 Years
7.5%
0%
7.5%
4 Years
-99.77%
0%
-99.77%
5 Years
-99.84%
0%
-99.84%

Vaccinex, Inc. for the last several years.

Risk Adjusted Returns v/s stock-summary
stock-summaryNews & Corporate Actions
News

Is Vaccinex, Inc. technically bullish or bearish?

As of 8 September 2025, the technical trend for Vaccinex, Inc. has changed from mildly bearish to bearish. The current technical stance is bearish with weak strength. Key indicators include bearish moving averages on the daily timeframe, a bearish KST on both weekly and monthly timeframes, and mildly bearish signals from Bollinger Bands. The MACD shows mildly bullish signals on the weekly and monthly, but this is overshadowed by the overall bearish trend. In terms of performance, the stock has underperformed significantly compared to the S&P 500, with a 1-year return of -86.43% versus the S&P 500's 17.14%, and a staggering -99.94% over the past 5 and 10 years....

Read More
Announcements stock-summary
Icon
No announcement available
Corporate Actions stock-summary
Icon
No corporate action available
stock-summaryKey Factors
Quality key factors stock-summary
Factor
Value
Sales Growth (5y)
1.55%
EBIT Growth (5y)
7.19%
EBIT to Interest (avg)
-21.78
Debt to EBITDA (avg)
Negative Net Debt
Net Debt to Equity (avg)
0.43
Sales to Capital Employed (avg)
-0.16
Tax Ratio
0
Dividend Payout Ratio
0
Pledged Shares
0
Institutional Holding
18.06%
ROCE (avg)
0
ROE (avg)
0
Valuation key factors
Factor
Value
P/E Ratio
NA (Loss Making)
Industry P/E
Price to Book Value
-0.92
EV to EBIT
-0.06
EV to EBITDA
-0.07
EV to Capital Employed
-0.34
EV to Sales
1.21
PEG Ratio
NA
Dividend Yield
NA
ROCE (Latest)
Negative Capital Employed
ROE (Latest)
Negative BV
Technicals key factors
Indicator
Weekly
Monthly
MACD
Mildly Bullish
Mildly Bullish
RSI
No Signal
Bullish
Bollinger Bands
Mildly Bullish
Mildly Bearish
Moving Averages
Mildly Bearish (Daily)
KST
Mildly Bullish
Bearish
Dow Theory
No Trend
No Trend
OBV
No Trend
Mildly Bearish
stock-summary Technical Indicator Scale: Bearish, Mildly Bearish, Sideways, Mildly Bullish, Bullish  Turned 
stock-summaryShareholding
Shareholding Snapshot : Dec 2024stock-summary
Shareholding Compare (%holding) stock-summary
Majority shareholders

Domestic Funds

Domestic Funds

Held in 3 Schemes (0.28%)

Foreign Institutions

Held by 5 Foreign Institutions (0.04%)

Strategic Entities with highest holding

Highest Public shareholder

stock-summaryFinancial
[
  {
    "link": "quarterly",
    "btn_text": "All Quarterly Results",
    "header": "Quarterly Results Snapshot (Consolidated) - Dec'24 - QoQ",
    "rhs": [
      {
        "prefix": "Net Sales ",
        "suffix": "QoQ Growth in quarter ended Dec 2024 is 100.00% vs -50.00% in Sep 2024",
        "dir": 1
      },
      {
        "prefix": "Consolidated Net Profit ",
        "suffix": "QoQ Growth in quarter ended Dec 2024 is 40.35% vs -1.79% in Sep 2024",
        "dir": 1
      }
    ],
    "table": {
      "header": [
        "Dec'24",
        "Sep'24",
        "Change(%)"
      ],
      "body": [
        {
          "field": "Net Sales",
          "val1": "0.20",
          "val2": "0.10",
          "chgp": "100.00%",
          "chgp_class": "positive"
        },
        {
          "field": "Operating Profit (PBDIT) excl Other Income",
          "val1": "-3.40",
          "val2": "-4.50",
          "chgp": "24.44%",
          "chgp_class": "positive"
        },
        {
          "field": "Interest",
          "val1": "0.00",
          "val2": "0.00",
          "chgp": "",
          "chgp_class": "neutral"
        },
        {
          "field": "Exceptional Items",
          "val1": "-0.00",
          "val2": "-0.10",
          "chgp": "100.00%",
          "chgp_class": "positive"
        },
        {
          "field": "Consolidate Net Profit",
          "val1": "-3.40",
          "val2": "-5.70",
          "chgp": "40.35%",
          "chgp_class": "positive"
        },
        {
          "field": "Operating Profit Margin (Excl OI)",
          "val1": "-15,901.40%",
          "val2": "-87,538.50%",
          "chgp": "7,163.71%",
          "chgp_class": "positive"
        }
      ]
    }
  },
  {
    "link": "annual",
    "btn_text": "All Annual Results",
    "header": "Annual Results Snapshot (Consolidated) - Dec'24",
    "rhs": [
      {
        "prefix": "Net Sales ",
        "suffix": "YoY Growth in year ended Dec 2024 is 0.00% vs 100.00% in Dec 2023",
        "dir": -1
      },
      {
        "prefix": "Consolidated Net Profit ",
        "suffix": "YoY Growth in year ended Dec 2024 is 8.37% vs -2.53% in Dec 2023",
        "dir": 1
      }
    ],
    "table": {
      "header": [
        "Dec'24",
        "Dec'23",
        "Change(%)"
      ],
      "body": [
        {
          "field": "Net Sales",
          "val1": "0.60",
          "val2": "0.60",
          "chgp": "",
          "chgp_class": "neutral"
        },
        {
          "field": "Operating Profit (PBDIT) excl Other Income",
          "val1": "-18.60",
          "val2": "-22.80",
          "chgp": "18.42%",
          "chgp_class": "positive"
        },
        {
          "field": "Interest",
          "val1": "0.00",
          "val2": "0.40",
          "chgp": "-100.00%",
          "chgp_class": "positive"
        },
        {
          "field": "Exceptional Items",
          "val1": "1.20",
          "val2": "2.10",
          "chgp": "-42.86%",
          "chgp_class": "negative"
        },
        {
          "field": "Consolidate Net Profit",
          "val1": "-18.60",
          "val2": "-20.30",
          "chgp": "8.37%",
          "chgp_class": "positive"
        },
        {
          "field": "Operating Profit Margin (Excl OI)",
          "val1": "-31,173.00%",
          "val2": "-40,149.10%",
          "chgp": "897.61%",
          "chgp_class": "positive"
        }
      ]
    }
  }
]
Quarterly Results Snapshot (Consolidated) - Dec'24 - QoQstock-summary
Dec'24
Sep'24
Change(%)
Net Sales
0.20
0.10
100.00%
Operating Profit (PBDIT) excl Other Income
-3.40
-4.50
24.44%
Interest
0.00
0.00
Exceptional Items
-0.00
-0.10
100.00%
Consolidate Net Profit
-3.40
-5.70
40.35%
Operating Profit Margin (Excl OI)
-15,901.40%
-87,538.50%
7,163.71%
USD in Million.
stock-summary Compare with Peers
Direction Arrows
Net Sales

QoQ Growth in quarter ended Dec 2024 is 100.00% vs -50.00% in Sep 2024

Direction Arrows
Consolidated Net Profit

QoQ Growth in quarter ended Dec 2024 is 40.35% vs -1.79% in Sep 2024

All Quarterly Resultsstock-summary
Annual Results Snapshot (Consolidated) - Dec'24stock-summary
Dec'24
Dec'23
Change(%)
Net Sales
0.60
0.60
Operating Profit (PBDIT) excl Other Income
-18.60
-22.80
18.42%
Interest
0.00
0.40
-100.00%
Exceptional Items
1.20
2.10
-42.86%
Consolidate Net Profit
-18.60
-20.30
8.37%
Operating Profit Margin (Excl OI)
-31,173.00%
-40,149.10%
897.61%
USD in Million.
stock-summary Compare with Peers
Direction Arrows
Net Sales

YoY Growth in year ended Dec 2024 is 0.00% vs 100.00% in Dec 2023

Direction Arrows
Consolidated Net Profit

YoY Growth in year ended Dec 2024 is 8.37% vs -2.53% in Dec 2023

All Annual Resultsstock-summary
stock-summaryCompany CV
About Vaccinex, Inc. stock-summary
stock-summary
Vaccinex, Inc.
Pharmaceuticals & Biotechnology
Vaccinex Inc. is a clinical-stage biotechnology company engaged in the discovery and development of targeted biotherapeutics. The Company is focused on providing treatments for serious diseases, including cancer, neurodegenerative diseases, and autoimmune disorders. It provides SEMA4D antibody platform, which is focused on developing its lead product candidate VX15/2503 (VX15) for the treatment of non-small cell lung cancer, NSCLC, osteosarcoma, melanoma and Huntington’s disease. It also provides ActiveMAb antibody discovery platform, a human antibody discovery platform used for expressing large and diverse libraries of high affinity, full-length human monoclonal antibodies on the surface of vaccinia, a mammalian virus. Its product candidate VX5 is in preclinical development for the treatment of multiple sclerosis and potentially for other autoimmune disorders.
Company Coordinates stock-summary
Company Details
1895 Mount Hope Ave , ROCHESTER NY : 14620-4540
stock-summary
Tel: 1 585 2712700
stock-summary
http://www.vaccinex.com/
stock-summary
Registrar Details
Stock List
ABCDEFGHIJKLMNOPQRSTUVWXYZOther
Footer Logo
InfinHub Market Technologies FZ-LLC, Building-2, Unit 112, Dubai Internet City, Dubai, United Arab Emirates
GET THE MARKETSMOJO APP
Company
Stocks
Portfolio
Market
Webinars
"Investment in securities markets are subject to market risk. Read all the related documents carefully before investing."